Abk�rzung zur Hauptnavigation Abk�rzung zu den Newsmeldungen Abk�rzung zu den Topstories  
  Barrierefreiheit    Kontakt MedUni Wien    Intranet    MedUni Wien - Shop    Universitätsbibliothek    Universitätsklinikum AKH Wien  
 
ccc_logo_en.gif
 
AKH Wien
 
 
Hauptnavigation
  • Livestream 2021
  • Home
  • Über das CCC
    • Allgemeines
    • Leitung der Organisationseinheit
    • CCC-Office Team
    • Kliniken und Partner
    • Qualitätsmanagement
    • Kontakt
  • PatientInnen
    • Covid-19
    • Allgemeines
    • Cancer School
    • Terminvereinbarung
    • Pflegeambulanz
    • PatientInnenvertretung
    • Links
  • Klinischer Bereich
    • Allgemeines
    • CCC Tumorboards
  • Wissenschaft & Forschung
    • Young CCC
    • CCC-ExpertInnenvideos
    • CCC Forschungscluster
    • CCC Units
    • CCC Platforms
    • Translationale Forschung
    • CCC Best Paper Award
    • CCC-TRIO Symposium
    • Kontakt/Links
  • Lehre
    • CCC Cancer School
    • Vienna International Summer School on Clinical and Experimental Oncology - VSSO
    • CCC Excellence Lecture
    • Interdisziplinäre onkologische Ausbildung
    • Klinisch-Praktisches Jahr (KPJ)
    • PhD Programme
    • Postgraduelle Fort- und Weiterbildung
    • Information/Contact
 
 
Subnavigation
    Inhaltsbereich


    Zurück zur Übersicht
    European urology. 2018 Jul 20. pii: S0302-2838(18)30484-6. doi: 10.1016/j.eururo.2018.07.006
    Comparison of Perioperative Outcomes Between Cytoreductive Radical Prostatectomy and Radical Prostatectomy for Nonmetastatic Prostate Cancer.
    Preisser F1,  Mazzone E2,  Nazzani S3,  Bandini M4,  Tian Z5,  Marchioni M6,  Steuber T7,  Saad F8,  Montorsi F9,  Shariat SF10,  Huland H11,  Graefen M12,  Tilki D13,  Karakiewicz PI14
    Author information
    1Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, Quebec, Canada; Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CR-CHUM), Montréal, Québec, Canada; Institut du Cancer de Montréal, Montréal, Québec, Canada; Martini-Klinik, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. Electronic address: felixpreisser@gmx.de.
    2Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, Quebec, Canada; Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CR-CHUM), Montréal, Québec, Canada; Institut du Cancer de Montréal, Montréal, Québec, Canada; Division of Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy; Vita-Salute San Raffaele University, Milan, Italy.
    3Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, Quebec, Canada; Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CR-CHUM), Montréal, Québec, Canada; Institut du Cancer de Montréal, Montréal, Québec, Canada; Academic Department of Urology, IRCCS Policlinico San Donato, University of Milan, Milan, Italy.
    4Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, Quebec, Canada; Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CR-CHUM), Montréal, Québec, Canada; Institut du Cancer de Montréal, Montréal, Québec, Canada; Division of Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy; Vita-Salute San Raffaele University, Milan, Italy.
    5Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, Quebec, Canada.
    6Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, Quebec, Canada; Department of Urology, SS Annunziata Hospital, "G. D'Annunzio" University of Chieti, Chieti, Italy.
    7Martini-Klinik, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
    8Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, Quebec, Canada; Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CR-CHUM), Montréal, Québec, Canada; Institut du Cancer de Montréal, Montréal, Québec, Canada.
    9Division of Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy; Vita-Salute San Raffaele University, Milan, Italy.
    10Department of Urology, Medical University of Vienna, Vienna, Austria.
    11Martini-Klinik, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
    12Martini-Klinik, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
    13Martini-Klinik, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Department of Urology, University Hospital Hamburg-Eppendorf, Hamburg, Germany.
    14Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, Quebec, Canada; Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CR-CHUM), Montréal, Québec, Canada; Institut du Cancer de Montréal, Montréal, Québec, Canada.
    Abstract

    Cytoreductive radical prostatectomy (CRP) may offer a survival advantage, according to several retrospective analyses. However, few data are available regarding the morbidity of radical prostatectomy in the metastatic setting. We addressed intra- and postoperative complications of CRP relative to radical prostatectomy for nonmetastatic prostate cancer (nmRP). Within the National Inpatient Sample database (2008-2013), we identified patients who underwent CRP versus nmRP. Propensity score matching to reduce the effect of inherent differences between CRP and nmRP patients, multivariable logistic regression models, Poisson regression models, and linear regression models were used. Of 76 378 patients, 1.2% (n=953) underwent CRP. CRP resulted in higher rates of overall (odds ratio [OR]: 1.34, p=0.01), intraoperative (OR: 2.61, p=0.005), and miscellaneous surgical complications (OR: 1.69, p=0.02). Moreover, CRP was associated with longer stay (OR: 1.07, p=0.01) and higher total hospital charges ($810 more per surgery, p=0.0004). Intra- and postoperative complications associated with CRP are higher than those of nmRP. Similarly, an increase in total hospital charges is associated with CRP. Nonetheless, CRP complication profile validates its safety and feasibility.

    PATIENT SUMMARY: In this population-based study, we recorded higher intra- and postoperative complications rates for CRP versus nmRP. Nonetheless, CRP complication rates appear manageable but require explicit discussion at counseling.


    Copyright © 2018 European Association of Urology. Published by Elsevier B.V. All rights reserved.

    KEYWORDS: Complications, Cytoreductive, Metastatic, National Inpatient Sample, Prostate cancer, Prostatectomy

    Publikations ID: 30037529
    Quelle: öffnen
     
    Drucken
     
    ccc_logo_en.gif
    ccc_logo_en.gif
    ccc_logo_en.gif

    Schnellinfo

     
    -- Initiative Krebsforschung / Krebsforschungslauf

    -- Cancer Care
    -- Kliniken und Partner
    -- CCC Cancer School
    -- Young CCC
    -- CCC Tumorboards
    -- CCC Forschungscluster
    -- CCC Units
    -- CCC Platforms
    -- SOPs / Leitlinien
    -- Kontakt
    Zuklappen
     
    Ausklappen
     
     

    Featured

     
     
     
     
     
     
     
     
     
     
     
     
     
    © MedUni Wien |
     Impressum | Nutzungsbedingungen | Kontakt